IMMX - NASDAQ

Immix Biopharma, Inc.

IMMX·NASDAQ

$8.63

+3.2%

HealthcareBiotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$469.57M

EPS-0.8900

P/E Ratio-9.70

Earnings Date08/14/2026

immx

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

60.16K

3-Year CAGR

-12%

5-Year CAGR

-15%

10-Year CAGR

-1%

Adjust for Inflation

Immix Biopharma, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

IMMX · NASDAQ

Company	Accumulated Other Comprehensive Income (Loss)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immix Biopharma, Inc. NASDAQ:IMMX	60.16K	-23.6%	-13.7%	N/A
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL	196.00K	-55.3%	N/A	N/A
Coya Therapeutics, Inc. NASDAQ:COYA	0.00	N/A	N/A	N/A
CAMP4 Therapeutics Corporation NASDAQ:CAMP	0.00	N/A	N/A	N/A
Artiva Biotherapeutics, Inc. NASDAQ:ARTV	103.00K	-30.6%	N/A	N/A
Clene Inc. NASDAQ:CLNN	172.00K	-4.7%	-5.9%	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	8.00K	-67.0%	N/A	N/A
CervoMed Inc. NASDAQ:CRVO	56.20K	N/A	N/A	N/A
Precision BioSciences, Inc. NASDAQ:DTIL	0.00	N/A	N/A	N/A
Gain Therapeutics, Inc. NASDAQ:GANX	776.87K	46.5%	N/A	N/A
XBiotech Inc. NASDAQ:XBIT	0.00	N/A	N/A	N/A

Immix Biopharma, Inc. Fair Value Envelope

IMMX · NASDAQ

Our analysis suggests that IMMX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.63, this represents a potential HIDDEN relative to our calculated worth for Immix Biopharma, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.63

Related Guides

Blog Categories

Continue your IMMX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.